Imagine a smart scanner that can spot the very first signs of vision loss before you even notice a change in your sight. It works like a high-tech 3D map of the eye, using AI to find tiny warning signs that humans might miss. This allows people to get help at their local optician instead of waiting for a specialist appointment at a big hospital.
Early AMD is hard to detect, and patients often only seek help when vision loss has already occurred. There is a lack of accessible, automated tools for non-specialists to predict disease progression accurately.
An AI-based diagnostic decision support system and a cloud-based platform for screening and monitoring AMD using OCT imaging.
If you are a local eye-care provider dealing with limited diagnostic tools — this project developed AI for low-cost devices that allows you to screen for intermediate AMD in your own office. This expands your service offering to 110 million individuals at risk.
If you are a digital health company dealing with the need for scalable diagnostic tools — this project developed a cloud-based infrastructure for joint data collection and AI implementation. It enables real-time monitoring of retinal biomarkers across multiple clinical sites.
If you are a biotech firm dealing with the need to identify patients for new AMD therapies — this project developed a personalized risk estimator of future disease progression. This helps target the right patients for the first approved therapies that halt atrophic AMD.
Based on available project data, specific pricing is not mentioned, but the project focuses on making the tools compatible with low-cost devices used in community settings.
Yes, the project uses a cloud-based platform and a network of 21 optometry sites and 7 clinics to ensure the AI works across different environments and device types.
Based on available project data, specific licensing terms are not provided, but the consortium includes 4 industry partners and 3 SMEs who are co-developing the technology.
The project aims to create a 'trustworthy AI' and aligns with recent regulatory approvals for AMD therapies to ensure clinical utility.
The project is active from 2024-01-01 to 2028-12-31, indicating a multi-year development and validation cycle.
The consortium is well-balanced for commercialization, featuring a 33% industry ratio with 4 industry partners, including 3 SMEs. The collaboration spans 8 countries and integrates 5 universities and 2 research institutes, ensuring a pipeline from academic AI research to practical cloud-based deployment and clinical validation.
Contact the Medical University of Vienna (Medizinische Universitaet Wien)
Contact us to explore licensing opportunities for the AI-based AMD risk estimator.
